Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Sánchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, Alva M, Echavarria I, Moreno F, Tolosa P, Herrero Lopez B, de Luna A, Lema L, Gamez Casado S, Madariaga A, López-Tarruella S, Manso L, Bueno-Muiño C, Garcia-Saenz JA, Ciruelos E, Martin M.
Sánchez-Bayona R, et al. Among authors: moreno f.
Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07324-8. Online ahead of print.
Breast Cancer Res Treat. 2024.
PMID: 38703285